Nurix Therapeutics reported a notably attenuated QQ1 2026 performance characterized by a small revenue base and a substantial operating loss. Revenue for QQ1 2026 stood at $6.25 million, down sharply from prior-year levels, with total operating expenses of $98.75 million driving an EBITDA of -$92.50 million and a net loss of -$87.17 million. The negative gross margin of -$77.89 million reflects the pre-revenue, early-stage nature of the business and its heavy reliance on R&D investment as it advances multiple BTK degrader programs (NX2127, NX5948) and other oncology/immunology candidates (NX1607, NX0255, DeTIL0255). Management commentary (as summarized from the earnings materials) emphasizes continued pipeline iteration, data-readouts, and potential strategic collaborations rather than immediate profitability. The near-term investment thesis hinges on successful clinical readouts, milestone discoveries, and meaningful licensing or collaboration monetization with major partners (notably Gilead and Sanofi). Absent fresh capital or material data-driven catalysts, Nurix faces a high-uncertainty, high-burn trajectory inherent to early-stage biopharma, albeit with potentially significant upside if pipeline progress translates into milestones and collaboration value.